Inozyme Pharma, Inc. (INZY)
NASDAQ: INZY · Real-Time Price · USD
3.970
+0.020 (0.51%)
At close: May 30, 2025, 4:00 PM
3.951
-0.020 (-0.49%)
After-hours: May 30, 2025, 4:13 PM EDT
Inozyme Pharma Stock Forecast
Stock Price Forecast
According to 9 professional analysts, the 12-month price target for Inozyme Pharma stock ranges from a low of $4.00 to a high of $30. The average analyst price target of $15.22 forecasts a 283.38% increase in the stock price over the next year.
Price Target: $15.22 (+283.38%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Inozyme Pharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 4 | 3 |
| Buy | 2 | 3 | 3 | 5 | 5 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 8 | 8 | 10 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy → Hold Downgrades $4 | Buy → Hold | Downgrades | $4 | +0.76% | May 16, 2025 |
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $15 → $4 | Strong Buy → Hold | Downgrades | $15 → $4 | +0.76% | May 16, 2025 |
| Needham | Needham | Strong Buy → Hold Downgrades $12 | Strong Buy → Hold | Downgrades | $12 | +202.27% | May 16, 2025 |
| Needham | Needham | Strong Buy Maintains $15 → $12 | Strong Buy | Maintains | $15 → $12 | +202.27% | May 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +303.02% | Apr 10, 2025 |
Financial Forecast
Revenue This Year
n/a
from 295.70M
Revenue Next Year
n/a
EPS This Year
-1.41
from -1.62
EPS Next Year
-1.15
from -1.41
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 39.2M | 131.1M | ||
| Avg | n/a | 5.4M | 36.2M | ||
| Low | n/a | n/a | 2.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 2,331.3% | ||
| Avg | - | - | 570.4% | ||
| Low | - | - | -45.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.09 | -0.38 | -0.41 | ||
| Avg | -1.41 | -1.15 | -1.03 | ||
| Low | -1.72 | -1.55 | -1.76 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.